NASDAQ OMX

IC Potash announces closing of Private Placement Financing and results of 2017 annual shareholders' meeting

Dela

TORONTO, June 29, 2017 (GLOBE NEWSWIRE) -- IC Potash Corp.  (TSX:ICP) (OTCQB:ICPTF) ("IC Potash" or the "Company") is pleased to announce the closing of a non-brokered private placement (the "Private Placement"). An aggregate of 16,738,808 units of the Company (the "Units") were issued at $0.05 per Unit for aggregate gross proceeds of $836,940.

Each Unit consists of (i) one common share of the Company (a "Common Share"); and (ii) one common share purchase warrant (each a "Warrant").  Each full Warrant entitles the holder to acquire one additional Common Share at an exercise price of $0.08 until June 28, 2018, provided that if, at any time after the date which is four months and one day following the Closing Date, the volume weighted average price of the Common Shares on the Toronto Stock Exchange (the "TSX") equals or exceeds $0.18 for 20 consecutive trading days, the Company may accelerate the expiry date of the Warrants, in which event the Warrants will expire upon the date (the "Accelerated Expiry Date") which is 30 days following the dissemination of a press release by the Company announcing the Accelerated Expiry Date. The Company paid a finder's fee of $14,000 and issued 280,000 broker warrants entitling the holder to acquire one Common Share for a period of 12 months at an exercise price equal to $0.06.

The proceeds will be used for working capital.

Further, the Company announced results of the voting at its annual meeting of shareholders (the "Meeting") held on June 28, 2017 in Toronto, Ontario, Canada.

At the Meeting, all director nominees listed in the Company's management information circular dated May 24, 2017 were elected as directors of the Company. The detailed results of the vote by ballot are as follows:


Election of Directors
    # of Votes
For
    % of Votes
For
    # of Votes
Withheld
    % of Votes
Withheld
John Stubbs     88,334,641     99.14 %     762,775     0.86 %
Mehdi Azodi     88,330,416     99.14 %     767,000     0.86 %
Hon. Pierre Pettigrew PC     88,334,416     99.14 %     763,000     0.86 %
Ernest Angelo, Jr.     88,332,516     99.14 %     764,900     0.86 %
Knute H. Lee, Jr.     88,332,116     99.14 %     765,300     0.86 %


In addition, 32,866,056 shares were voted by proxy in favour of the election of all directors, but, were received late and were not included in the above-referenced results.

At the Meeting, shareholders re-appointed Davidson & Company LLP as auditors of the Company.

About IC Potash Corp.
IC Potash has previously demonstrated a method to make Sulfate of Potash ("SOP") from the Ochoa polyhalite deposit in Southeast New Mexico in which it has an interest and is currently examining ways to become a low-cost fertilizer producer. The current review of the Ochoa project's existing feasibility study is being extended to determine a viable positive economic path to the production of direct application polyhalite. The Ochoa project has access to excellent local labor resources, low-cost electricity and natural gas, water, rail lines, and the Port of Galveston, Texas. The Ochoa project's land holdings consist of nearly 90,000 acres of potassium prospecting permits and mining leases issued by the U.S. Bureau of Land Management and State of New Mexico. For more information, please visit www.icpotash.com.

Forward-Looking Statements
Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties and other factors which may cause the actual results, performance or achievements of IC Potash to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements include statements that use forward-looking terminology such as "may", "will", "expect", "anticipate", "believe", "continue", "potential" or the negative thereof or other variations thereof or comparable terminology. Such forward-looking statements include, without limitation, statements regarding trends in the markets for Sulfate of Potash and polyhalite, the timing for completion of an updated feasibility study by the Company, the Company's intention to investigate the feasibility of polyhalite product production, the potential value of water resources and other statements that are not historical facts. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of IC Potash, including, but not limited to, changes in market trends, the completion, results and timing of studies undertaken by IC Potash, risks associated with mineral exploration and mining activities, the impact of general economic conditions, commodity prices, industry conditions, dependence upon regulatory and environmental approvals, the uncertainty of obtaining additional financing, and risks associated with turning reserves into product. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements.

For More Information, Please Contact: 
IC Potash Corp.    
Mr. Mehdi Azodi, +1-416-779-3268 
Chief Executive Officer
MAZODI@ICPOTASH.ORG




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: IC Potash Corp. via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

Leading Medical Organizations Update Guideline for Molecular Testing and Targeted Therapies in Lung Cancer23.1.2018 21:11Pressmeddelande

DENVER, Jan. 23, 2018 (GLOBE NEWSWIRE) -- Rapid advancements in the molecular diagnostic testing of lung cancer have led to new treatments and greater hope for patients battling lung cancer, the most common cause of cancer death worldwide. To ensure that clinicians stay apace and provide optimal patient care, three leading medical societies-the College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association for Molecular Pathology (AMP)-have updated their 2013 evidence-based guideline. Published today in early online release, the "Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Kinase Inhibitors," continues to set standards for the molecular analysis of lung cancers for test results that effectively guide targeted therapy and treatment. Targeted cancer therapies are drugs or other treatments that block the spread of cancer by interfering with specific molec

CashBet Seeks $40 Million for World's Only Complete Crypto-Ready Mobile iGaming Platform23.1.2018 16:31Pressmeddelande

Gaming and cryptocurrency industry leaders develop blockchain-based iGaming platform improving trust, speed, access, costs, and content availability OAKLAND, Calif., Jan. 23, 2018 (GLOBE NEWSWIRE) -- Leading mobile-first iGaming platform provider CashBet (https://coin.cashbet.com/) today announced it seeks to raise $40 million through an Initial Coin Offering (ICO) to develop the world's first complete crypto-ready mobile iGaming platform. Interactive gaming, which includes real money, social, skill-based, esports and sports betting, hit $91 billion in 2016, led by mobile gaming. Despite strong growth, current iGaming operations continue to face three major issues: trust, speed, and cost. CashBet is the first and only vertically integrated iGaming solution to leverage blockchain technology for transparent operations, increased speed, and lower transaction fees. The CashBet Coin will be available in pre-sale starting January 24, 2018 at 5:00 p.m. GMT, with a 20 percent discount offered.

BrandSafway Announces Acquisition of Venko Groep BV23.1.2018 16:30Pressmeddelande

Combined customers to benefit from broader range of services and greater depth of expertise KENNESAW, GA, Jan. 22, 2018 (GLOBE NEWSWIRE) -- Brand Industrial Services, known as BrandSafway, has acquired Venko Groep BV, a portfolio company of Mentha Capital, effective January 1, 2018. Moving forward, the company will operate as Venko, A BrandSafway Company and become a part of Brand Energy & Infrastructure Services (Brand) in Europe. "We're excited to announce the closing of the acquisition of Venko," said Dave Witsken, President of Energy and Industrial for BrandSafway. "Venko is a leading offshore coatings maintenance provider for platforms in Europe. By leveraging the highly specialized knowledge and capabilities of Venko, we will be able to provide expanded coatings services to Brand's European customers. At the same time, with our support, Venko will now be able to offer their customers a broader inventory of access equipment and additional industrial services, such as insulation an

Data on Novel Humanized Models for Targeted Immunotherapy Development, a CrownBio Conference Talk on January 24th, 201823.1.2018 14:53Pressmeddelande

SAN DIEGO, Jan. 23, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, will unveil data supporting use of its cost-effective, humanized drug target models at the Tumor Models Conference in San Francisco tomorrow, Wednesday, January 24th, 2018. Humanized research tools are crucial to the development of target-specific immunotherapies like pembrolizumab and ipilimumab. To help improve research in this burgeoning field, CrownBio has developed a humanized platform that informs the preclinical pharmacology of targeted immunotherapies, including solutions for PD-1, PD-L1, OX40, and CD3E. Constituent models feature fully functional murine immunity with humanized drug targets that can be used in conjunction with syngeneic tumor cell lines engineered to expr

Music Legend Joey Fatone Will Be Celebrity Grand Marshal Of First Ever 15th Annual World's Shortest St. Patrick's Day Parade In Hot Springs, Arkansas23.1.2018 13:56Pressmeddelande

HOT SPRINGS NATIONAL PARK, Ark., Jan. 23, 2018 (GLOBE NEWSWIRE) -- Music legend Joey Fatone, who soared to worldwide fame as a member of boy-band *NSYNC, will be celebrity grand marshal of the First Ever 15th Annual World's Shortest St. Patrick's Day Parade in downtown Hot Springs March 17, 2018, reports Hot Springs Convention & Visitors Bureau. He'll round out a quartet of celebrities who will be part of the quirky parade, which annually draws throngs to world-famous Bridge Street, the shortest street in the world in everyday use - 98 feet long. Jon Heder, who became famous as Napoleon Dynamite, will be the parade's official starter. The 2018 parade will begin at 7:30 p.m., an hour later than previous years. The start time was changed to allow Oaklawn racing fans plenty of time to enjoy the live racing including The Rebel Stakes at Oaklawn Park, and still get downtown for the start of the parade. Morris Day and the Time will perform a free concert at the conclusion of the parade. On F

HemCheck och Region Västmanland i studie om hemolyserade blodgasprov23.1.2018 13:30Pressmeddelande

PRESSMEDDELANDE HemCheck och Region Västmanland i studie om hemolyserade blodgasprov Karlstad 23 januari 2018: HemCheck Sweden AB meddelar idag att bolaget tecknat ett avtal med Region Västmanland avseende en studie för att kartlägga förekomsten av hemolys i blodgasprover tagna vid akutmottagningen på Västmanlands Sjukhus i Västerås. Blodgasanalys är ett blodprov som tas rutinmässigt på sjukhus och som är ett centralt verktyg när snabba svar krävs för kritiska diagnoser. Blodgasanalysen påverkas, liksom vanlig blodprovstagning, av hemolys, men i vilken omfattning är ännu inte lika väl dokumenterat. -Idag utförs ingen hemolyskontroll på blodgasprov. Avsikten med studien är att undersöka förekomsten av hemolys i blod som analyserats i blodgasapparater och se om det kan detekteras med hjälp av ett enkelt test. Det är glädjande att vi som ett första steg i det arbetet kan genomföra en så viktig studie ihop med Region Västmanland och Västmanlands Sjukhus Västerås. Vi ser att väl fungerande

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum